MAP2K7 and melanoma: It has been previously described that the MEK inhibitor trametinib rapidly induces hyper-phosphorylation of HER3 tyrosine kinase receptor in a panel of melanoma cell lines harboring a variety of BRAFV600E/K mutations [35].